(a) No payment in excess of the amount of reimbursement of direct expenses incurred as a result of the procedure shall be made to any subject to encourage the subject to produce human oocytes for the purposes of medical research.
(b) This section shall become operative on January 1, 2024.
(Repealed (in Sec. 7) and added by Stats. 2019, Ch. 864, Sec. 8. (AB 922) Effective January 1, 2020. Section operative January 1, 2024, by its own provisions.)